Imaging of ¹⁸⁶Re-liposome therapy in ovarian cancer xenograft model of peritoneal carcinomatosis

References

• Agarwal R, Linch M, Kaye SB. Novel therapeutic agents in ovarian cancer. Eur J Surg Oncol 2006; 32: 875–886
   PubMed Web of Science ®Google Scholar
• Bao A, Goins B, Klipper R, Negrete G, Phillips WT. 186Re-liposome labeling using 186Re-SNS/S complexes: In vitro stability, imaging, and biodistribution in rats. J Nucl Med 2003; 44: 1992–1999
   PubMed Web of Science ®Google Scholar
• Bao A, Goins B, Klipper R, Negrete G, Phillips WT. Direct 99mTc labeling of pegylated liposomal doxorubicin (Doxil) for pharmacokinetic and non-invasive imaging studies. J Pharmacol Exp Ther 2004; 308: 419–425
   PubMed Web of Science ®Google Scholar
• Buchsbaum DJ, Khazaeli MB, Axworthy DB, Schultz J, Chaudhuri TR, Zinn KR, Carpenter M, LoBuglio AF. Intraperitoneal pretarget radioimmunotherapy with CC49 fusion protein. Clin Cancer Res 2005; 11: 8180–8185
   PubMed Web of Science ®Google Scholar
• Caliceti P, Chinol M, Roldo M, Veronese FM, Semenzato A, Salmaso S, Paganelli G. Poly(ethylene glycol)–avidin bioconjugates: Suitable candidates for tumor pretargeting. J Control Release 2002; 83: 97–108
   PubMed Web of Science ®Google Scholar
• Cannistra SA. Intraperitoneal chemotherapy comes of age. N Engl J Med 2006; 354: 77–79
   PubMed Web of Science ®Google Scholar
• Chan JK, Cheung MK, Husain A, Teng NN, West D, Whittemore AS, Berek JS, Osann K. Patterns and progress in ovarian cancer over 14 years. Obstet Gynecol 2006; 108: 521–528
   PubMed Web of Science ®Google Scholar
• Chen LC, Chang CH, Yu CY, Chang YJ, Hsu WC, Ho CL, Yeh CH, Luo TY, Lee TW, Ting G. Biodistribution, pharmacokinetics and imaging of (188)Re-BMEDA-labeled pegylated liposomes after intraperitoneal injection in a C26 colon carcinoma ascites mouse model. Nucl Med Biol 2007; 34: 415–423
   PubMed Web of Science ®Google Scholar
• Chinol M, Casalini P, Maggiolo M, Canevari S, Omodeo ES, Caliceti P, Veronese FM, Cremonesi M, Chiolerio F, Nardone E, et al. Biochemical modifications of avidin improve pharmacokinetics and biodistribution, and reduce immunogenicity. Br J Cancer 1998; 78: 189–197
   PubMed Web of Science ®Google Scholar
• Coliva A, Zacchetti A, Luison E, Tomassetti A, Bongarzone I, Seregni E, Bombardieri E, Martin F, Giussani A, Figini M, et al. 90Y Labeling of monoclonal antibody MOv18 and preclinical validation for radioimmunotherapy of human ovarian carcinomas. Cancer Immunol Immunother 2005; 54: 1200–1213
   PubMed Web of Science ®Google Scholar
• de Bree E, Witkamp AJ, Zoetmulder FA. Intraperitoneal chemotherapy for colorectal cancer. J Surg Oncol 2002; 79: 46–61
   PubMed Web of Science ®Google Scholar
• Deutsch E, Libson K, Vanderheyden JL, Ketring AR, Maxon HR. The chemistry of rhenium and technetium as related to the use of isotopes of these elements in therapeutic and diagnostic nuclear medicine. Int J Rad Appl Instrum B 1986; 13: 465–477
   PubMedGoogle Scholar
• Elgqvist J, Andersson H, Back T, Hultborn R, Jensen H, Karlsson B, Lindegren S, Palm S, Warnhammar E, Jacobsson L. Therapeutic efficacy and tumor dose estimations in radioimmunotherapy of intraperitoneally growing OVCAR-3 cells in nude mice with (211)At-labeled monoclonal antibody MX35. J Nucl Med 2005; 46: 1907–1915
   PubMed Web of Science ®Google Scholar
• Gadducci A, Cosio S, Conte PF, Genazzani AR. Consolidation and maintenance treatments for patients with advanced epithelial ovarian cancer in complete response after first-line chemotherapy: A review of the literature. Crit Rev Oncol Hematol 2005; 55: 153–166
   PubMed Web of Science ®Google Scholar
• Grana C, Bartolomei M, Handkiewicz D, Rocca P, Bodei L, Colombo N, Chinol M, Mangioni C, Malavasi F, Paganelli G. Radioimmunotherapy in advanced ovarian cancer: Is there a role for pre-targeting with (90)Y-biotin?. Gynecol Oncol 2004; 93: 691–698
   PubMed Web of Science ®Google Scholar
• Gunn AJ, Brechbiel MW, Choyke PL. The emerging role of molecular imaging and targeted therapeutics in peritoneal carcinomatosis. Expert Opin Drug Deliv 2007; 4: 389–402
   PubMed Web of Science ®Google Scholar
• Hagenbeek A. Future trends in radioimmunotherapy. Semin Oncol 2005; 32: S57–S62
   PubMed Web of Science ®Google Scholar
• Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007, CA. Cancer J Clin 2007; 57: 43–66
   PubMed Web of Science ®Google Scholar
• Koppe MJ, Postema EJ, Aarts F, Oyen WJ, Bleichrodt RP, Boerman OC. Antibody-guided radiation therapy of cancer. Cancer Metastasis Rev 2005; 24: 539–567
   PubMed Web of Science ®Google Scholar
• Markman M. Intraperitoneal drug delivery of antineoplastics. Drugs 2001; 61: 1057–1065
   PubMed Web of Science ®Google Scholar
• Markman M. Intraperitoneal antineoplastic drug delivery: Rationale and results. Lancet Oncol 2003; 4: 277–283
   PubMed Web of Science ®Google Scholar
• McQuarrie S, Mercer J, Syme A, Suresh M, Miller G. Preliminary results of nanopharmaceuticals used in the radioimmunotherapy of ovarian cancer. J Pharm Pharm Sci 2005; 7: 29–34
   PubMedGoogle Scholar
• Medina LA, Calixto SM, Klipper R, Li Y, Phillips WT, Goins B. Mediastinal node and diaphragmatic targeting after intracavitary injection of avidin/99mTc-blue-biotin–liposome system. J Pharm Sci 2006; 95: 207–224
   PubMed Web of Science ®Google Scholar
• Meredith RF, Buchsbaum DJ, Alvarez RD, LoBuglio AF. Brief overview of preclinical and clinical studies in the development of intraperitoneal radioimmunotherapy for ovarian cancer. Clin Cancer Res 2007; 13: 5643s–5645s
   PubMed Web of Science ®Google Scholar
• Munoz-Casares FC, Rufian S, Rubio MJ, Lizarraga E, Diaz-Iglesias C, Aranda E, Ciria R, Muntane J, Barrios P, Torres-Melero J, et al. Treatment of peritoneal carcinomatosis from ovarian cancer. Present, future directions and proposals. Clin Transl Oncol 2007; 9: 652–662
   PubMed Web of Science ®Google Scholar
• Oriuchi N, Higuchi T, Hanaoka H, Iida Y, Endo K. Current status of cancer therapy with radiolabeled monoclonal antibody. Ann Nucl Med 2005; 19: 355–365
   PubMed Web of Science ®Google Scholar
• Parker RJ, Hartman KD, Sieber SM. Lymphatic absorption and tissue disposition of liposome-entrapped [14C]adriamycin following intraperitoneal administration to rats. Cancer Res 1981a; 41: 1311–1317
   PubMed Web of Science ®Google Scholar
• Parker RJ, Sieber SM, Weinstein JN. Effect of liposome encapsulation of a fluorescent dye on its uptake by the lymphatics of the rat. Pharmacology 1981b; 23: 128–136
   PubMed Web of Science ®Google Scholar
• Phillips WT, Klipper R, Goins B. Use of (99m)Tc-labeled liposomes encapsulating blue dye for identification of the sentinel lymph node. J Nucl Med 2001; 42: 446–451
   PubMed Web of Science ®Google Scholar
• Phillips WT, Medina LA, Klipper R, Goins B. A novel approach for the increased delivery of pharmaceutical agents to peritoneum and associated lymph nodes. J Pharmacol Exp Ther 2002; 303: 11–16
   PubMed Web of Science ®Google Scholar
• Reddy LH, Murthy RS. Pharmacokinetics and biodistribution studies of Doxorubicin loaded poly(butyl cyanoacrylate) nanoparticles synthesized by two different techniques. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2004; 148: 161–166
   PubMedGoogle Scholar
• Sadzuka Y, Hirama R, Sonobe T. Effects of intraperitoneal administration of liposomes and methods of preparing liposomes for local therapy. Toxicol Lett 2002; 126: 83–90
   PubMed Web of Science ®Google Scholar
• Schneider JG. Intraperitoneal chemotherapy. Obstet Gynecol Clin North Am 1994; 21: 195–212
   PubMed Web of Science ®Google Scholar
• Stewart JC. Colorimetric determination of phospholipids with ammonium ferrothiocyanate. Anal Biochem 1980; 104: 10–14
   PubMed Web of Science ®Google Scholar
• Twardowski ZJ. History of peritoneal access development. Int J Artif Organs 2006; 29: 2–40
   PubMed Web of Science ®Google Scholar
• Varia MA, Stehman FB, Bundy BN, Benda JA, Clarke-Pearson DL, Alvarez RD, Long HJ. Intraperitoneal radioactive phosphorus (32P) versus observation after negative second-look laparotomy for stage III ovarian carcinoma: A randomized trial of the Gynecologic Oncology Group. J Clin Oncol 2003; 21: 2849–2855
   PubMed Web of Science ®Google Scholar
• Woodward PJ, Hosseinzadeh K, Saenger JS. From the archives of the AFIP: Radiologic staging of ovarian carcinoma with pathologic correlation. Radiographics 2004; 24: 225–246
   PubMed Web of Science ®Google Scholar
• Xiao Z, McQuarrie SA, Suresh MR, Mercer JR, Gupta S, Miller GG. A three-step strategy for targeting drug carriers to human ovarian carcinoma cells in vitro. J Biotechnol 2002; 94: 171–184
   PubMed Web of Science ®Google Scholar
• Young RC, Brady MF, Nieberg RK, Long HJ, Mayer AR, Lentz SS, Hurteau J, Alberts DS. Adjuvant treatment for early ovarian cancer: A randomized phase III trial of intraperitoneal 32P or intravenous cyclophosphamide and cisplatin—a gynecologic oncology group study. J Clin Oncol 2003; 21: 4350–4355
   PubMed Web of Science ®Google Scholar
• Zavaleta CL, Phillips WT, Bradley YC, McManus LM, Jerabek PA, Goins BA. Characterization of an intraperitoneal ovarian cancer xenograft model in nude rats using noninvasive microPET imaging. Int J Gynecol Cancer 2007a; 17: 407–417
   PubMed Web of Science ®Google Scholar
• Zavaleta CL, Phillips WT, Soundararajan A, Goins BA. Use of avidin/biotin-liposome system for enhanced peritoneal drug delivery in an ovarian cancer model. Int J Pharm 2007b; 337: 316–328
   PubMedGoogle Scholar
• Zweit J. Radionuclides and carrier molecules for therapy. Phys Med Biol 1996; 41: 1905–1914
   PubMed Web of Science ®Google Scholar